This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Backers include societies representing radiologists and nuclear medicine professionals, device manufacturers, patient advocacy groups, and pharmaceutical companies.
Patient Care Solutions is one of GEHCs four individual segments, along with Imaging, Advanced Visualization Solutions, and PharmaceuticalDiagnostics. Tom Westrick, who is retiring after more than 20 years with GEHC, will remain with the company until May 31 to support Bankes transition into the role.
milla1cf Tue, 01/23/2024 - 13:50 January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich , Member of the Board of Management, Bayer AG, and President Pharmaceuticals.
Australia-based Telix Pharmaceuticals has filed with the U.S. For the quarter (end-September 30), Telix reported: Total revenue of approximately $135 million ($201 million AUD), primarily generated from sales of Telix’s prostate cancer imaging product Illuccix in its precision medicine (Px) business unit. the company said.
Bracco subsidiary Blue Earth Diagnostics has appointed a new CEO. Marco Campione will report to Bracco Imaging CEO Fulvio Renoldi Bracco and will join Blue Earth Diagnostics' board of directors.
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., subject to its regulatory approval. If approved , Zircaix will be the first targeted PET agent specifically for kidney cancer to be commercially available in the U.S., the company noted.
GE HealthCare (GEHC) reported a 1% growth in existing operation revenues and an increase in profitability in its second quarter of 2024, citing solid performance in its PharmaceuticalDiagnostics segment. On an individual segment basis, GE HealthCare's Imaging segment had flat revenues year over year of $2.22 last year to 16.3%
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Bracco Imaging S.p.A.,
On an individual segment basis, GE HealthCare's Imaging segment had revenues of $2.596 billion, down 1% from $2.62 However, organic imaging revenue was $2.62 Imaging EBIT increased by 3% to reach $286 million. PharmaceuticalDiagnostics segment EBIT was $200 million, up 31% over last year. last year to 15.3%
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.
Clarity Pharmaceuticals has secured fast-track designation from the U.S. The classification builds on Clarity's earlier receipt of fast-track designation for its PET diagnosticimaging agent Cu-64 SAR-bisPSMA for identifying patients with the disease.
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, and PSI CRO, a global contract research organization, plan to conduct a trial using Clarity's phase III diagnostic trial of Clarify for prostate cancer patients.
Telix Pharmaceuticals has entered an agreement to acquire Canadian diagnosticimaging isotopes company ARTMS for $82 million. The companies have been collaborating since 2020 to develop higher curie-scale production of Illuccix, a PET radiotracer injection kit used for prostate cancer imaging.
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnosticimaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.
The scanner also comes with True Enhance DL, an AI-based application that generates deep learning-based monochromatic-like images from a single-energy x-ray acquisition. GEHC also pointed to upgrades for its Revolution Apex scanner, including ECG-less Cardiac for acquiring cardiac images without the need for an ECG signal or trace.
Telix Pharmaceuticals has inked a deal to acquire Florida-based radiopharmacy network RLS Radiopharmacies for up to $250 million, the companies announced. Telix’s lead imaging product is Illuccix, a gallium-68-based PET radiotracer injection kit used in prostate cancer imaging. RLS is a current distributor of Illuccix.
"By not separating radiologist assistant reimbursement policies into different payment categories by service location, the adoption of MARCA would enable radiologists to devote more focused time to reviewing and interpreting complex medical images or urgent cases," the ASRT has said.
based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology. Financial terms were not disclosed.
The study will also then help identify early response to immunotherapies, using sequential whole-body imaging to monitor CD8 changes over time, enabling physicians to switch patients who are not responding to alternative treatment options sooner. For more information: www.gehealthcare.com References: Shankar L.
is the only FDA approved FES PET imaging agent. Currently, when treating metastatic breast cancer patients, oncologists base clinical decisions on diagnostic tools including biopsy results which only represent the sampled area of the tumor. GE HealthCare’s Cerianna , available in the U.S.,
milla1cf Wed, 06/21/2023 - 19:47 June 21, 2023 — Fresenius Kabi , a leading provider of injectable medicines, announced today it has launched the diagnosticpharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc. ’s s Kinevac (Sincalide for Injection) product.
The company reports that the major update delivers the industry’s first multi-AI workflows, which simultaneously display results from more than one application in Proscia’s precision medicine AI portfolio on the same image. Not for use in diagnostic procedures. “We Concentriq AP is for research use only.
The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.
The scientists will then use artificial intelligence and machine learning to analyze the image data, linked to relevant patient data on demographics, treatment history and pre-existing conditions. tim.hodson Tue, 01/21/2025 - 13:17 Jan.
Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. An active DMF enables clinical investigators or pharmaceutical companies to reference the filing in their regulatory submissions. a subsidiary of BWX Technologies, Inc.
i] In a July 19 statement announcing the published research, Bracco Imaging added that it has launched gadopiclenol as VUEWAY (gadopiclenol) solution for injection and VUEWAY (gadopiclenol) Pharmacy Bulk Package, following the 2022 approval of gadopiclenol by the United States Food and Drug Administration (U.S. [ii],
milla1cf Fri, 05/05/2023 - 17:31 May 5, 2023 — The American College of Radiology ( ACR ), Breast Cancer Research Foundation (BCRF) and GE HealthCare announce the enrollment of the first patients in the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST).
The agents affected include some of the most widely used contrast products in medical imaging. The recommendation was issued by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), the primary body in the European Union responsible for regulating pharmaceuticals.
christine.book Thu, 03/21/2024 - 10:34 March 21, 2024 — Diagnosticimaging provider US Radiology Specialists has announced that Lee Cooper will become its new Chief Executive Officer (CEO), and that current board member Molly Joseph will become its next Board Chair. Cooper and Joseph will succeed John Perkins , U.S.
The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.
GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.
milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.
produced, non-uranium based Mo-99 for use in diagnosticimaging. In parallel with these initiatives, NorthStar’s imaging portfolio continues to advance,” Mr. Merrick further added. imaging studies daily. Our track record of success includes our program to supply U.S.-produced,
Proscia’s Concentriq AP-Dx is a comprehensive diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images and helps to drive confidence and efficiency gains. It can also streamline collaboration, broadening access to expertise. Reference: 1.
The prospective multicenter trial, which is slated to begin patient recruitment in late 2023, will reportedly assess the ability of 64Cu SAR-bisPSMA to diagnose prostate cancer within pelvic lymph nodes.
Sarcopenia is an inevitable symptom of aging, and yet there are no pharmaceutical interventions to prevent or address the issue. Springbok’s lower extremity (LE) scan takes under 10 minutes of imaging time, and its full body scan can be done in less than 40 minutes.
milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceuticaldiagnostics, and digital solutions innovator, and MediView XR Inc., Disclaimer: OmnifyXR is intended to be used adjunctively to standard of care imaging.
After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support. Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. 3] Shankar L.
a pioneer in AI -driven predictive analytics using multi-modal data including text, signal, and image (US Patent No.11263749) In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics. milla1cf Mon, 11/20/2023 - 12:27 November 20, 2023 — InMed.AI (InMed Prognostics Inc.),
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceuticaldiagnostics, and digital portfolio.
The rise of precision medicine is putting new pressures on diagnostic laboratories to tap into their pathology data, as whole slide images are among the best representations of disease. The same spatial mapping will also enable Nucleai’s applications to serve as companion diagnostics that match patients to the most effective treatment.
christine.book Thu, 09/07/2023 - 12:19 September 7, 2023 — Paige , a provider of end-to-end digital pathology solutions and clinical AI, has announced a collaboration with Microsoft to build what they refer to as the world’s largest image-based AI models for digital pathology and oncology.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content